Jorge Máspero, María Valeria Angles, Ledit Ardusso, Milagros Brancciforte, Carla Castro, Carmen Cruz Iturrieta, Ezequiel Chouela, Mónica Silvia De Gennaro, Ramón Fernández Bussy, María Laura Galimberti, Ricardo Luis Galimberti, Gabriel Gattolin, Paula Carolina Luna, Gabriel Magariños, Mariano Gabriel Marini, Matías Maskin, Romina Plafnik, Nélida Raimondo, Juan Pedro Russo, Luis Sevinsky, Matías Federico Stringa
Introduction: Severe atopic dermatitis (AD) treatment is an unmet need, given the limited efficacy and safety of classical systemic treatments (CSTs). Dupilumab is a monoclonal antibody that blocks the signaling of the interleukins that mediate the inflammatory response involved in AD. Methods: the clinical response of a group of patients from Argentina with severe AD and insufficient response and/or toxicity to CSTs who were treated with dupilumab before commercial availability was analyzed...
June 9, 2020: Revista de la Facultad de Ciencias Médicas